您的浏览器禁用了JavaScript(一种计算机语言,用以实现您与网页的交互),请解除该禁用,或者联系我们。[开源证券]:港股公司首次覆盖报告:中医连锁服务龙头企业,国际化布局持续推进 - 发现报告

港股公司首次覆盖报告:中医连锁服务龙头企业,国际化布局持续推进

2025-07-22余汝意、阮帅开源证券M***
AI智能总结
查看更多
港股公司首次覆盖报告:中医连锁服务龙头企业,国际化布局持续推进

固生堂(02273.HK)2025年07月22日投资评级:买入(首次)日期2025/7/22当前股价(港元)35.900一年最高最低(港元)48.950/25.500总市值(亿港元)流通市值(亿港元)总股本(亿股)流通港股(亿股)近3个月换手率(%)股价走势图数据来源:聚源-40%-20%0%20%40%60%2024-072024-112025-03固生堂恒生指数 1/272027E5,78823.8764027.4530.1911.0516.282.7012.01.95 84.7384.7349.76 目录1、固生堂:国内中医医疗连锁服务龙头....................................................................................................................................41.1、股权布局清晰稳健,资深高管掌舵领航......................................................................................................................51.2、业绩高速增长,盈利能力持续提升..............................................................................................................................62、供需共振,中医医疗服务市场市场规模较快增长...................................................................................................................82.1、需求端:人口老龄化与慢性病持续加剧,中医诊疗需求不断释放..........................................................................92.2、政策端:多项利好政策持续加码,中医医疗服务行业有望持续增长....................................................................112.3、供给端:优质中医医师资源稀缺,民营中医诊疗服务市场扩容明显....................................................................122.4、中国中医医疗资源正处于供需失衡局面....................................................................................................................142.5、中医医疗服务行业进入壁垒较高...............................................................................................................................143、OMO生态深化融合,国际化布局加速推进..........................................................................................................................153.1、公司打造相辅相成的线上线下OMO服务模式........................................................................................................153.2、内生外延并举,公司迈出国际化第一步....................................................................................................................153.3、持续加强医联体建设,推动名医AI分身落地.........................................................................................................173.4、供应链稳定,院内制剂给公司带来新增长点............................................................................................................203.5、多渠道获取客户获取,客户留存战略与会员制度促成客户高黏性........................................................................214、盈利预测与投资建议..............................................................................................................................................................224.1、关键假设.......................................................................................................................................................................224.2、盈利预测与估值...........................................................................................................................................................235、风险提示..................................................................................................................................................................................24附:财务预测摘要..........................................................................................................................................................................25图表目录图1:公司股权结构清晰,实控人持股比例超三成(2024年报披露)...................................................................................5图2:公司营收高速增长...............................................................................................................................................................6图3:公司归母净利润扭亏为盈,持续攀升................................................................................................................................6图4:公司医疗健康解决方案业务收入持续占主导地位............................................................................................................7图5:公司医疗健康解决方案业务毛利占比超96%...................................................................................................................7图6:公司于2024年迈出国际化第一步.....................................................................................................................................7图7:公司营收以线下业务为主,线上实现小幅提升................................................................................................................7图8:近五年公司整体毛利率维持稳定.......................................................................................................................................8图9:公司两大主营业务毛利率保持在较高水平........................................................................................................................8图10:公司三费整体呈下降趋势,降本增效成果显著..............................................................................................................8图11:预计中国中医医疗服务市场规模快速扩大......................................................................................................................9图12:国内人口老龄化程度持续提升.......................................................................................................................................10图13:居民慢性病患病率持续攀升(单位:‰)....................................................................................................................10图14:人均可支配收入不断增加带动中医医疗需求日趋多样化.....